NASPE/ACC/AHA/ESC medical/scientific statement special report--clinical investigation of antiarrhythmic devices

a statement for healthcare professionals from a Joint Task Force of the North American Society of Pacing and Electrophysiology, the American College of Cardiology, the American Heart Association, and the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of

S. Saksena, A. E. Epstein, R. Lazzara, J. D. Maloney, D. P. Zipes, D. G. Benditt, A. J. Camm, M. J. Domanski, John Devens Fisher, B. J. Gersh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The goal of radiofrequency catheter ablation and the criterion for efficacy is the elimination of arrhythmogenic myocardium. The application of radiofrequency current in the heart clearly results in lower morbidity and mortality rates than thoracic and cardiac surgical procedures in general, and comparisons of therapy with radiofrequency catheter ablation and therapy with thoracic and cardiac surgical procedures in randomized clinical trials are unwarranted. Trials of radiofrequency catheter ablation versus medical or implantable cardioverter defibrillator therapy may be indicated in certain conditions, such as ventricular tachycardia associated with coronary artery disease. Randomized trials are recommended for new and radical departures in technology that aim to accomplish the same goals as radiofrequency catheter ablation. Surveillance using registries and/or databases is necessary in the assessment of long-term safety and efficacy.

Original languageEnglish (US)
Pages (from-to)637-654
Number of pages18
JournalPACE - Pacing and Clinical Electrophysiology
Volume18
Issue number4 Pt 1
StatePublished - Apr 1995
Externally publishedYes

Fingerprint

Catheter Ablation
Electrophysiology
Advisory Committees
Cardiac Arrhythmias
Thoracic Surgical Procedures
Joints
Cardiac Surgical Procedures
Delivery of Health Care
Equipment and Supplies
Implantable Defibrillators
Ventricular Tachycardia
Registries
Coronary Artery Disease
Myocardium
Therapeutics
Randomized Controlled Trials
Databases
Technology
Morbidity
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{fb009dd9b37546f685dca955907faa6f,
title = "NASPE/ACC/AHA/ESC medical/scientific statement special report--clinical investigation of antiarrhythmic devices: a statement for healthcare professionals from a Joint Task Force of the North American Society of Pacing and Electrophysiology, the American College of Cardiology, the American Heart Association, and the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of",
abstract = "The goal of radiofrequency catheter ablation and the criterion for efficacy is the elimination of arrhythmogenic myocardium. The application of radiofrequency current in the heart clearly results in lower morbidity and mortality rates than thoracic and cardiac surgical procedures in general, and comparisons of therapy with radiofrequency catheter ablation and therapy with thoracic and cardiac surgical procedures in randomized clinical trials are unwarranted. Trials of radiofrequency catheter ablation versus medical or implantable cardioverter defibrillator therapy may be indicated in certain conditions, such as ventricular tachycardia associated with coronary artery disease. Randomized trials are recommended for new and radical departures in technology that aim to accomplish the same goals as radiofrequency catheter ablation. Surveillance using registries and/or databases is necessary in the assessment of long-term safety and efficacy.",
author = "S. Saksena and Epstein, {A. E.} and R. Lazzara and Maloney, {J. D.} and Zipes, {D. P.} and Benditt, {D. G.} and Camm, {A. J.} and Domanski, {M. J.} and Fisher, {John Devens} and Gersh, {B. J.}",
year = "1995",
month = "4",
language = "English (US)",
volume = "18",
pages = "637--654",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "4 Pt 1",

}

TY - JOUR

T1 - NASPE/ACC/AHA/ESC medical/scientific statement special report--clinical investigation of antiarrhythmic devices

T2 - a statement for healthcare professionals from a Joint Task Force of the North American Society of Pacing and Electrophysiology, the American College of Cardiology, the American Heart Association, and the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of

AU - Saksena, S.

AU - Epstein, A. E.

AU - Lazzara, R.

AU - Maloney, J. D.

AU - Zipes, D. P.

AU - Benditt, D. G.

AU - Camm, A. J.

AU - Domanski, M. J.

AU - Fisher, John Devens

AU - Gersh, B. J.

PY - 1995/4

Y1 - 1995/4

N2 - The goal of radiofrequency catheter ablation and the criterion for efficacy is the elimination of arrhythmogenic myocardium. The application of radiofrequency current in the heart clearly results in lower morbidity and mortality rates than thoracic and cardiac surgical procedures in general, and comparisons of therapy with radiofrequency catheter ablation and therapy with thoracic and cardiac surgical procedures in randomized clinical trials are unwarranted. Trials of radiofrequency catheter ablation versus medical or implantable cardioverter defibrillator therapy may be indicated in certain conditions, such as ventricular tachycardia associated with coronary artery disease. Randomized trials are recommended for new and radical departures in technology that aim to accomplish the same goals as radiofrequency catheter ablation. Surveillance using registries and/or databases is necessary in the assessment of long-term safety and efficacy.

AB - The goal of radiofrequency catheter ablation and the criterion for efficacy is the elimination of arrhythmogenic myocardium. The application of radiofrequency current in the heart clearly results in lower morbidity and mortality rates than thoracic and cardiac surgical procedures in general, and comparisons of therapy with radiofrequency catheter ablation and therapy with thoracic and cardiac surgical procedures in randomized clinical trials are unwarranted. Trials of radiofrequency catheter ablation versus medical or implantable cardioverter defibrillator therapy may be indicated in certain conditions, such as ventricular tachycardia associated with coronary artery disease. Randomized trials are recommended for new and radical departures in technology that aim to accomplish the same goals as radiofrequency catheter ablation. Surveillance using registries and/or databases is necessary in the assessment of long-term safety and efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0002723502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002723502&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 637

EP - 654

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 4 Pt 1

ER -